U.S. Markets open in 3 hrs 30 mins

Guardion Health Sciences, Inc. (GHSI)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.1813-0.0364 (-16.72%)
At close: 4:00PM EDT

0.1813 0.00 (0.00%)
Before hours: 4:33AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2177
Open0.2099
Bid0.1773 x 1100
Ask0.1813 x 1000
Day's Range0.1750 - 0.2099
52 Week Range0.1650 - 0.7400
Volume9,514,526
Avg. Volume3,698,375
Market Cap16.014M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1420
Earnings DateAug 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders’ Meeting
    GlobeNewswire

    Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders’ Meeting

    SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing the following answers to frequently asked questions to its stockholders with regard to Proposal 4, which is being considered at the Company’s Annual Stockholders’ Meeting (the “Annual Meeting”) on October 29, 2020. Only stockholders of record on September 1, 2020, or the record date, are eligible to attend and vote on proposals presented at the Annual Meeting. The Board recommends a vote “FOR” Proposal 4. IMPORTANT REMINDER FOR GUARDION HEALTH SCIENCES, INC. STOCKHOLDERSTime is short – please vote your shares for the Annual Meeting of Stockholders on October 29, 2020Your vote may impact the value of your investment and the future of Guardion Health Sciences, Inc.KEY QUESTIONS OUR STOCKHOLDERS ARE ASKING REGARDING PROPOSAL 4: EXTENSION OF PREVIOUSLY AUTHORIZED REVERSE STOCK SPLITQuestionAnswer What will happen to Guardion Health Sciences, Inc. if Proposal 4 (Extension of Previously Authorized Reverse Stock Split) does not pass?  Your vote “FOR” Proposal 4 at the Annual Meeting of Stockholders on October 29, 2020 is critically important. Guardion Health Sciences, Inc. is at risk of being delisted from the Nasdaq Capital Market after November 30, 2020. Such delisting would adversely impact the liquidity of the Company’s common stock. Nasdaq requires that a Company maintain a minimum bid price of $1.00 per share. The Company is requesting from its stockholders an extension of its current authorization to effectuate a reverse stock split (which expires December 5, 2020) to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq. Additionally, a reverse stock split would potentially make the Company’s common stock more attractive to certain institutional investors, which would provide for a stronger investor base.   If Proposal 4 is not approved, the Board of Directors will initiate the previously authorized reverse stock split in November 2020 in order to comply with Nasdaq’s continued listing requirements.   If Proposal 4 is approved, we intend to appeal any delisting order that Nasdaq issues after November 30, 2020, as we believe that having the continuing discretionary authority to implement a reverse stock split will increase the Company’s chances of receiving temporary relief (not to exceed 180 days from November 30, 2020) from Nasdaq. Such temporary relief will allow the Company additional time to execute on its business initiatives to generate greater stockholder value and hopefully increase the Company’s common share price.   The board of directors believes it is in your best interest to vote “FOR” Proposal 4 today.    Didn’t Stockholders authorize a Reverse Stock Split at last year’s annual meeting? Why is my vote so important?  Yes, our stockholders authorized a reverse stock split at last year’s annual meeting of stockholders to be effectuated up until December 5, 2020. To date, the Board of Directors has not implemented the reverse stock split. We are requesting an extension of that previous authorization from our stockholders so that our Board of Directors retains the flexibility necessary should a reverse stock split become necessary.   Approval of Proposal 4 requires support by at least a majority of the outstanding shares of common stock. So, while many Guardion Health Sciences, Inc. stockholders have been highly supportive of Proposal 4 to date, we have not yet received enough votes to meet that high standard. That is why your vote matters, no matter how many or how few common shares you own.   What happens if I don’t vote?If you don’t vote or you abstain, it may count the same as a vote AGAINST Proposal 4.   Who can help me vote?Our proxy solicitor, Kingsdale Advisors, can assist you with voting your shares and any questions you may have – please see below for their contact information.   If I’ve already voted, can I change my vote?Yes. You may revoke your previously submitted proxy and reclaim your right to vote at any time before your proxy is voted at the Annual Meeting by submitting a later-dated proxy card or vote instruction form or by voting in person at the Annual Meeting. Your most current proxy card or Internet proxy is the one that will be counted. Your vote is important, so please act today!   Our proxy solicitor, Kingsdale Advisors, can assist in this process as well – please see below for their contact information. OUR PROXY SOLICITOR (KINGSDALE ADVISORS) STANDS READY TO ASSIST YOU WITH THIS IMPORTANT VOTE If you have questions about how to vote your shares, please contact our proxy solicitor, Kingsdale Advisors Strategic Stockholder Advisor and Proxy Solicitation Agent 745 Fifth Avenue, 5th Floor, New York, NY 10151 North American Toll Free Phone: 1-866-229-8874 Email: contactus@kingsdaleadvisors.com Call Collect Outside North America: +1 (416) 867-2272 * * *This communication may be deemed to be solicitation material in respect of Proposal 4. On September 8, 2020, Guardion Health Sciences, Inc. filed a definitive proxy statement with the Securities and Exchange Commission (“Commission”) in connection with the 2020 Annual Stockholders’ Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS THAT ARE FILED WITH THE COMMISSION WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS TO BE VOTED UPON. The Company’s proxy statement and any other solicitation materials filed by the Company with the Commission can be obtained free of charge at the Commission’s website at www.sec.gov and at the investor relations section of the Company’s website at https://guardionhealth.com/sec-filings/. Stockholders may also write to the Company at the following address to request copies of these materials: Guardion Health Sciences, Inc., 15150 Avenue of Science, Suite 200, San Diego, California 92128. The Company, its directors and certain of its officers will be participants in the solicitation of proxies from stockholders in respect of the Annual Meeting. The Company has also engaged Kingsdale Advisors to aid in the solicitation of proxies. Detailed information regarding the identity of participants, and their respective interests in the Company by security holdings or otherwise, are set forth in the definitive proxy statement for the Annual Meeting. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement. Forward-Looking Statement DisclaimerWith the exception of the historical information contained in this press release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact:CORE IR Scott Arnold 516-222-2560 scotta@coreir.com

  • Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z
    GlobeNewswire

    Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

    SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, announced an investigator-initiated clinical trial of Lumega-Z, its flagship nutritional product which is now being marketed under the NutriGuard brand. This clinical trial, which is part of the Company’s on-going investigator-driven studies program to support clinical claims for the Company’s proprietary products, is designed to evaluate the impact of Lumega-Z on the restoration of the macular pigment and its relationship to the stabilization or recovery of vision. Depletion of the macular pigment at the back of the eye is a risk factor for vision loss related to age-related macular degeneration (“AMD”), glaucoma and other serious eye diseases. The clinical study, which is being conducted by William E. “Rick” Sponsel, M.D., will focus on patients with eye disease and will evaluate the impact that the macular pigment has on stabilizing and/or restoring visual function and other clinical measures. Dr. Sponsel is a world-renowned expert in ocular physiology, ocular circulation and innovative techniques for treating eye diseases. After serving as Director of Clinical Research at the University of Texas, Dr. Sponsel transitioned into private practice in San Antonio, Texas. His practice focuses on patients with advanced ocular disease, including macular generation, diabetic retinopathy and glaucoma. Dr. Sponsel continues to serve as Professor of Vision Sciences at UIW and Professor of Biomedical Engineering at UTSA. Over his 30-year career, Dr. Sponsel has published more than 100 peer-reviewed papers and numerous book chapters.The clinical study will compare the macular pigment and other clinical measures in patients taking Lumega-Z against patients not taking Lumega-Z or any other ocular nutrition product. The study will focus on glaucoma patients with controlled intraocular pressure, but who continue to have vision problems, and will compare results from 30 patients who have taken Lumega-Z daily for 12 months to 30 similar patients who are not on a regimen of Lumega-Z or any other ocular nutrition product.“As the nutrition market continues to grow and attracts more focus from other players like Abbott and Nestle, it is essential that Guardion continues to differentiate itself through measurable clinical outcomes provided by our nutrition and medical food brands,” commented David Evans, Ph.D., Guardion’s interim President and Chief Executive Officer, and Chief Science Officer. “Dr. Sponsel’s research project represents a pivotal part of this differentiation strategy, and we believe that the results of his study could have a significant impact on how consumers, patients and physicians use nutritional products as part of an integrated treatment approach to support ocular health and manage certain debilitating eye conditions, as well as overall health and immunity.”“This clinical study is part of our strategy to initiate investigator-driven clinical trials conducted with Guardion’s unique nutritional products,” added Dr. Evans. “We expect to be announcing further clinical trials, as well as potential timelines for results in the near-term, and we look forward to updating our shareholders on additional progress and developments.”About Guardion Health SciencesGuardion is a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace. Located in San Diego, California, the Company combines targeted nutrition with innovative, evidence-based diagnostic technology. Guardion boasts impressive Scientific and Medical Advisory Boards. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.Forward-Looking Statement Disclaimer With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact: CORE IR Scott Arnold 516-222-2560 scotta@coreir.comMedia Relations Contact: Jules Abraham Director of Public Relations CORE IR 917-885-7378 julesa@coreir.com

  • We Think Guardion Health Sciences (NASDAQ:GHSI) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Guardion Health Sciences (NASDAQ:GHSI) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...